# Kymera Therapeutics Q3 2026 Earnings Call

> Kymera Therapeutics CEO discusses Phase I trial results for KT-579.
- Title: Kymera Therapeutics Q3 2026 Earnings Call · Seekingalpha
- Summary: Kymera Therapeutics CEO discusses Phase I trial results for KT-579. Kymera Therapeutics reported Q3 2026 earnings with Phase I trial results for KT-579.
- Keywords: kymera therapeutics, q3 2026, earnings call, kt-579, phase i trial, investor relations, money, business, Kymera, Therapeutics, 2026, Earnings
- Source: Seekingalpha — https://seekingalpha.com/article/4959588-kymera-therapeutics-inc-kymr-q3-2026-earnings-call-transcript
- Author: SA Transcripts
- Published: 2026-10-29T18:28:50+00:00
- Read time: 1 min
- Topics: kymera therapeutics, q3 2026, earnings call, kt-579, phase i trial, investor relations, money, business
## Q3 2026 Earnings Call
Kymera Therapeutics held Q3 2026 earnings call on October 29, 2026.
## Company Participants
Justine Koenigsberg, Nello Mainolfi, Terence Rooney, and Bruce Jacobs joined the call.
## KT-579 Phase I Results
The call discussed KT-579 Phase I healthy volunteer trial results.
## Key takeaway

Kymera Therapeutics reported Q3 2026 earnings with Phase I trial results for KT-579.